Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope Medical Center
Duarte, California, United States
Alex F. HerreraRecruiting - University of Chicago Cancer Research Center
Chicago, Illinois, United States
Recruiting - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Recruiting - Hackensack University Medical Center/john Theurer Cancer Center
Hackensack, New Jersey, United States
Recruiting - Sarah Cannon Research Institute
Nashville, Tennessee, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 12 Nov 2021
- Primary completion
- 2 Oct 2026
- Completion
- 2 Oct 2026
- Last update posted
- 24 Sept 2025
- Registered enrollment
- 31
- Registry id
- NCT04561206
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.